Joel Snover
Medical · Allen Park, MINPI 1528721867
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 357 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 22.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,377, 9.9 times the $342 reported in 2022. Among medical clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 357 payments — averaging $22.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- AbbVie$872
- Lilly USA, LLC$770
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$565
- Novo Nordisk$468
- Pfizer$446
- plus $3K from 29 others
What the payments were for
- Food & beverage$8,104100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 50 | $1,833 |
| AbbVie | 40 | $872 |
| Lilly USA, LLC | 38 | $770 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 37 | $565 |
| Novo Nordisk | 27 | $468 |
| Pfizer | 27 | $446 |
| Otsuka America Pharmaceutical, Inc. | 16 | $409 |
| Amgen(2 entities) | 9 | $378 |
| Boehringer Ingelheim | 12 | $239 |
| Novartis | 11 | $216 |
| Bayer | 8 | $208 |
| Johnson & Johnson | 8 | $199 |
| Idorsia Pharmaceuticals US Inc | 7 | $194 |
| GSK | 11 | $177 |
| Exact Sciences | 10 | $169 |
| Aimmune Therapeutics, Inc. | 2 | $135 |
| Lundbeck LLC | 6 | $110 |
| Axsome Therapeutics, Inc. | 6 | $105 |
| Astellas Pharma US Inc | 5 | $100 |
| Amneal Pharmaceuticals LLC | 4 | $92 |
| Antares Pharma, Inc. | 3 | $67 |
| Abbott | 4 | $59 |
| Sanofi-aventis U.S. LLC | 2 | $47 |
| Halozyme Inc | 2 | $40 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| Alkermes, Inc. | 1 | $24 |
| Merck | 1 | $23 |
| Hologic Sales And Service, LLC | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Ironwood Pharmaceuticals, Inc | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Verona Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,104 in reported general payments places this provider in the 90th percentile of 755 medical providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 63 | $39,487 |
| OzempicSemaglutide | 25 | $32,430 |
| JardianceEmpagliflozin | 32 | $27,474 |
| EliquisApixaban | 29 | $24,506 |
| MounjaroTirzepatide | 18 | $19,284 |
| FarxigaDapagliflozin Propanediol | 11 | $9,393 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 375 | $7,849 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,322 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $3,972 |
| Tolterodine Tartrate ErTolterodine Tartrate | 17 | $2,120 |
| Colesevelam Hcl | 19 | $1,929 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 72 | $1,823 |
| Alprazolam | 245 | $1,769 |
| Gabapentin | 138 | $1,449 |
| Omeprazole | 99 | $1,375 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $177 | $43,80974 claims |
| Novo NordiskOzempic | $468 | $32,43025 claims |
| Boehringer IngelheimJardiance | $239 | $27,47432 claims |
| PfizerEliquis | $446 | $24,50629 claims |
| Lilly USA, LLCMounjaro | $770 | $19,28418 claims |
| AstraZenecaFarxiga, Symbicort | $1,833 | $13,36529 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $92 | $1,02884 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 755 medical providers in Michigan.
Other medical in Allen Park
- Caleb YoungbloodBerkley$215K
- Steven StoneKalamazoo$200K
- Meredith KentGrand Rapids$192K
- Amber ShullNorton Shores$154K
- Jason EvansWaterford$104K
- James ToreySaint Clair Shores$56K
- David WilkinsMuskegon$41K
- Mark RosenBerkley$32K
- Robert DemeesterRoyal Oak$27K
- John BrabantDetroit$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.